185 related articles for article (PubMed ID: 8879230)
21. Cellular localisation of HHV-8 in Castleman's disease: is there a link with lymph node vascularity?
O'Leary J; Kennedy M; Howells D; Silva I; Uhlmann V; Luttich K; Biddolph S; Lucas S; Russell J; Bermingham N; O'Donovan M; Ring M; Kenny C; Sweeney M; Sheils O; Martin C; Picton S; Gatter K
Mol Pathol; 2000 Apr; 53(2):69-76. PubMed ID: 10889905
[TBL] [Abstract][Full Text] [Related]
22. Castleman's disease in a 44-year-old male with neurofibromatosis and pheochromocytoma.
Stelfox HT; Stewart AK; Bailey D; Harrison D
Leuk Lymphoma; 1997 Nov; 27(5-6):551-6. PubMed ID: 9477139
[TBL] [Abstract][Full Text] [Related]
23. Systemic connective tissue disease complicated by Castleman's disease: report of a case and review of the literature.
De Marchi G; De Vita S; Fabris M; Scott CA; Ferraccioli G
Haematologica; 2004 Apr; 89(4):ECR03. PubMed ID: 15075095
[TBL] [Abstract][Full Text] [Related]
24. A composite C/EBP binding site is essential for the activity of the promoter of the IL-3/IL-5/granulocyte-macrophage colony-stimulating factor receptor beta c gene.
van Dijk TB; Baltus B; Raaijmakers JA; Lammers JW; Koenderman L; de Groot RP
J Immunol; 1999 Sep; 163(5):2674-80. PubMed ID: 10453008
[TBL] [Abstract][Full Text] [Related]
25. Absence of gallium uptake in unicentric and multicentric Castleman's disease.
Okamoto I; Iyonaga K; Fujii K; Mori T; Yoshioka M; Kohrogi H; Matsumoto M; Suga M
Intern Med; 2003 Aug; 42(8):735-9. PubMed ID: 12924503
[TBL] [Abstract][Full Text] [Related]
26. Ornithine decarboxylase gene expression in Castleman's disease.
Malaguarnera L; Pilastro MR; Vicari L; Di Marco R; Malaguarnera M; Messina A
J Mol Med (Berl); 1999 Nov; 77(11):798-803. PubMed ID: 10619440
[TBL] [Abstract][Full Text] [Related]
27. Expression of interleukin-6 in Castleman's disease.
Hsu SM; Waldron JA; Xie SS; Barlogie B
Hum Pathol; 1993 Aug; 24(8):833-9. PubMed ID: 8375854
[TBL] [Abstract][Full Text] [Related]
28. Report of a case of localized Castleman's disease with progression to malignant lymphoma.
Vasef M; Katzin WE; Mendelsohn G; Reydman M
Am J Clin Pathol; 1992 Dec; 98(6):633-6. PubMed ID: 1462961
[TBL] [Abstract][Full Text] [Related]
29. The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms.
Ramji DP; Vitelli A; Tronche F; Cortese R; Ciliberto G
Nucleic Acids Res; 1993 Jan; 21(2):289-94. PubMed ID: 7680115
[TBL] [Abstract][Full Text] [Related]
30. A transitional variant of Castleman's disease presenting as a chylous pleural effusion.
Ten Hoor T; Hewan-Lowe K; Miller JI; Moss M
Chest; 1999 Jan; 115(1):285-8. PubMed ID: 9925102
[TBL] [Abstract][Full Text] [Related]
31. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
[TBL] [Abstract][Full Text] [Related]
32. [Is there a place for interferon-alpha in the treatment strategy of multicentric Castleman's disease?].
Maloisel F; Andrès E; Campos F; Opréa C; Deslandres M; Randriamahazaka R; Kurtz JE; Koumarianou A; Dufour P
Rev Med Interne; 2000 May; 21(5):435-8. PubMed ID: 10874763
[TBL] [Abstract][Full Text] [Related]
33. Impaired generation of bone marrow B lymphocytes in mice deficient in C/EBPbeta.
Chen X; Liu W; Ambrosino C; Ruocco MR; Poli V; Romani L; Quinto I; Barbieri S; Holmes KL; Venuta S; Scala G
Blood; 1997 Jul; 90(1):156-64. PubMed ID: 9207449
[TBL] [Abstract][Full Text] [Related]
34. Castleman's disease of the neck.
Chen CC; Jiang RS; Chou G; Wang CP
J Chin Med Assoc; 2007 Dec; 70(12):556-8. PubMed ID: 18194898
[TBL] [Abstract][Full Text] [Related]
35. Regulation of CCAAT/enhancer binding protein isoforms by serum and glucocorticoids in the rat intestinal epithelial crypt cell line IEC-6.
Boudreau F; Blais S; Asselin C
Exp Cell Res; 1996 Jan; 222(1):1-9. PubMed ID: 8549649
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 receptor expression in the peripheral B cells of patients with multicentric Castleman's disease.
Ishiyama T; Koike M; Nakamura S; Kakimoto T; Akimoto Y; Tsuruoka N
Ann Hematol; 1996 Oct; 73(4):179-82. PubMed ID: 8890706
[TBL] [Abstract][Full Text] [Related]
37. Multicentric Castleman's disease in human immunodeficiency virus infection: two case reports.
Caroline Ribeiro Sales A; Romão de Souza Junior V; Iglis de Oliveira M; Azevedo Braga Albuquerque C; de Barros Campelo Júnior E; Sérgio Ramos de Araújo P
J Med Case Rep; 2018 May; 12(1):117. PubMed ID: 29728131
[TBL] [Abstract][Full Text] [Related]
38. [Idiopathic multicentric Castleman's disease].
Vasilyev VI; Palshina SG; Pavlovskaya AI; Kokosadze NV; Chaltsev BD; Shornikova LA
Ter Arkh; 2020 Jun; 92(5):78-84. PubMed ID: 32598779
[TBL] [Abstract][Full Text] [Related]
39. Lipopolysaccharide-mediated induction of the bovine interleukin-6 gene in monocytes requires both NF-kappa B and C/EBP binding sites.
Ray A; Ray BK
DNA Cell Biol; 1995 Sep; 14(9):795-802. PubMed ID: 7669256
[TBL] [Abstract][Full Text] [Related]
40. Immunologic study of the hyaline-vascular type of Castleman's disease. A case study.
Kimura H; Watanabe Y; Ohashi N; Kobayashi M; Asai M; Mizukoshi K
Acta Otolaryngol Suppl; 1993; 504():146-50. PubMed ID: 8470523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
